Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Gains from Investment Securities: 2016-2024

  • Sunshine Biopharma's Gains from Investment Securities was N/A to -$373,529 in Q4 2024 from the same period last year, while for Dec 2024 it was $582,483, marking a year-over-year change of. This contributed to the annual value of $582,483 for FY2024, which is N/A change from last year.
  • Per Sunshine Biopharma's latest filing, its Gains from Investment Securities stood at -$373,529 for Q4 2024, which was down 139.07% from $956,012 recorded in Q1 2024.
  • In the past 5 years, Sunshine Biopharma's Gains from Investment Securities registered a high of $956,012 during Q1 2024, and its lowest value of -$373,529 during Q4 2024.
  • Over the past 1 years, Sunshine Biopharma's median Gains from Investment Securities value was $291,242 (recorded in 2024), while the average stood at $291,242.